• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email
    SC 13G/A 1 ctmx1015241sc13ga3.htm AMENDMENT NO.3

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3) *

     

     

    CytomX Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

     

     

    23284F105

    (CUSIP Number)

     

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Page 1 of 10
     

     

    CUSIP No. 23284F105

     

     

    13G/A Page 2 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) ¨

     

    ( b) ¨

     

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    7,811,760

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    7,811,760

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    7,811,760

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

    12

    type of reporting person

     

    OO 

     

    Page 2 of 10
     

     

    CUSIP No. 23284F105

     

     

    13G/A Page 3 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) ¨

     

    ( b) ¨

     

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    7,811,760

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    7,811,760

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    7,811,760

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

    12

    type of reporting person

     

    IN 

     

    Page 3 of 10
     

     

    CUSIP No. 23284F105

     

     

    13G/A Page 4 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) ¨

     

    ( b) ¨

     

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    7,811,760

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    7,811,760

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    7,811,760

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

    12

    type of reporting person

     

    PN 

     

    Page 4 of 10
     

     

    CUSIP No. 23284F105

     

     

    13G/A Page 5 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS III, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) ¨

     

    ( b) ¨

     

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

    12

    type of reporting person

     

    CO 

     

    Page 5 of 10
     

     

    CUSIP No. 23284F105

     

     

    13G/A Page 6 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS IV, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) ¨

     

    ( b) ¨

     

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

    12

    type of reporting person

     

    CO 

     

    Page 6 of 10
     

     

    Item 1(a).Name of Issuer:

     

    CytomX Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and the Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations which are indirectly wholly owned by Tang Capital Partners.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.00001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 23284F105

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 7,811,760 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 7,811,760 shares of the Issuer’s Common Stock. 

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    Page 7 of 10
     

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 7,811,760 shares of the Issuer’s Common Stock. 

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 78,117,601 shares of Common Stock outstanding as of July 31, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 8, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 9.99%
    Kevin Tang 9.99%
    Tang Capital Partners 9.99%
    Tang Capital Partners III 0.00%

    Tang Capital Partners IV

    0.00%

     

    (c)Number of shares as to which such person has:

     

    (i)       sole power to vote or to direct the vote:

     

      Tang Capital Management 0 shares
      Kevin Tang 0 shares
      Tang Capital Partners 0 shares
      Tang Capital Partners III 0 shares
      Tang Capital Partners IV 0 shares

     

    (ii)      shared power to vote or to direct the vote:

     

      Tang Capital Management 7,811,760 shares
      Kevin Tang 7,811,760 shares
      Tang Capital Partners 7,811,760 shares
      Tang Capital Partners III 0 shares
      Tang Capital Partners IV 0 shares

     

    (iii)     sole power to dispose or to direct the disposition of:

     

      Tang Capital Management 0 shares
      Kevin Tang 0 shares
      Tang Capital Partners 0 shares
      Tang Capital Partners III 0 shares
      Tang Capital Partners IV 0 shares

     

    (iv)     shared power to dispose or to direct the disposition of:

     

      Tang Capital Management 7,811,760 shares
      Kevin Tang 7,811,760 shares
      Tang Capital Partners 7,811,760 shares
      Tang Capital Partners III 0 shares
      Tang Capital Partners IV 0 shares

     

    Page 8 of 10
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 9 of 10
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: 

    November 14, 2024

     

     

     

    TANG CAPITAL PARTNERS, LP

     

    By:  Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL PARTNERS III, INC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  
         
         

    TANG CAPITAL PARTNERS IV, INC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  
         

         

    TANG CAPITAL MANAGEMENT, LLC

     
       

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 10 of 10

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $CTMX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    5/6/2024$2.50 → $8.00Hold → Buy
    Jefferies
    4/22/2024Underweight → Neutral
    JP Morgan
    11/14/2022$3.00 → $2.60Outperform → Market Perform
    BMO Capital Markets
    7/7/2022$16.00 → $4.00Buy → Neutral
    Mizuho
    More analyst ratings

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, on

      5/29/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

      SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma. CX-801 is a dually masked interferon (IFN) alpha-2b PROBODY® cytokine. CX-801 has been intentionally designed by CytomX to harness the power of Interferon alpha-2b's immune stimulating properties in combination with checkpoint inhibition. In

      5/19/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

      SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions. The Company int

      5/12/25 6:50:52 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    SEC Filings

    See more
    • SEC Form 8-K filed by CytomX Therapeutics Inc.

      8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)

      5/28/25 4:06:12 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

      SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      5/15/25 4:15:24 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by CytomX Therapeutics Inc.

      8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)

      5/13/25 4:05:20 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Mccarthy Sean A. sold $22,556 worth of shares (37,656 units at $0.60), decreasing direct ownership by 4% to 995,195 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:34:40 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Ogden Christopher sold $5,122 worth of shares (8,551 units at $0.60), decreasing direct ownership by 4% to 201,026 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:33:49 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Chu Yu-Waye sold $2,411 worth of shares (4,025 units at $0.60), decreasing direct ownership by 3% to 135,725 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:32:56 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Financials

    Live finance-specific insights

    See more
    • CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 Phase 1 data update expected by Q1 2026 - - Planning CX-2051 Phase 2 study initiation in 1H 2026 - - CX-801 (PROBODY® Interferon alpha-2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Company to host conference call today at 8 a.m. EST / 5 a.m. PST - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics,

      5/12/25 6:15:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

      - 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median progression free survival of 5.8 months as of April 7th 2025 data cutoff - - Encouraging initial safety profile with no dose limiting toxicities at data cutoff - - Planning Phase 2 study initiation in 1H 2026 - - Conference call on Monday, May 12 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, to

      5/12/25 6:15:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

      SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to j

      5/5/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 4:26:32 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 4:00:06 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 3:03:21 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    See more

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

      3/21/24 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company's diversified portfolio of Probody® therapeutic candidates. "Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "His drug development experiences have contributed to multiple approvals and span therapeutic modalitie

      7/17/23 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company's next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation. "I would like to express my s

      4/14/22 4:15:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded CytomX Therapeutics from Neutral to Buy and set a new price target of $5.00

      5/15/25 8:05:24 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on CytomX Therapeutics with a new price target

      Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously

      4/14/25 8:16:21 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously

      5/28/24 7:31:35 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care